The eight p11 (8p11) myeloproliferative syndrome (EMS) term is designated in the 2008 World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues 1 as myeloid and lymphoid neoplasms with eosinophilia and abnormalities of fibroblast growth factor receptor 1 gene (FGFR1). These aggressive malignancies are characterized by their rare occurrence, heterogeneity, eosinophilia and rapid progression in acute myeloid leukemia. The fibroblast growth factor receptor 1 gene (FGFR1) encodes for a tyrosine kinase receptor for fibroblast growth factor and is known to be fused to different recurrent gene partners, such as TPR 2 (1q25), LRRFIP1 (2q37), FGFR1OP1 (6q27), CUX1 (ref.
3) (7q22), TRIM24 (7q34), CEP110 (9q33), FGFR1OP2 (12p11), CPSF6 (12q15), ZNF198 (13q12), MYO18A (17q23), HERV-K (19q13) and BCR (22q11), reviewed in Jackson et al. 4 In all cases the chimeric protein contains an aberrant tyrosine kinase domain constitutively activated. Treatments, including tyrosine kinase inhibitors based regimen, are often ineffective so that FGFR1 abnormalities are associated with bad prognosis. The few long-term survivors have undergone stem cell allograft.
We report here a novel partner gene for FGFR1, identified in a 63-year old Caucasian female. The patient was referred to our institution for dyspnea, impaired general condition and splenomegaly without hepatomegaly nor adenopathy. Medical history included a severe stroke following the rupture of a cerebral aneurysm, a mitral valve replacement and an ischemic cardiopathy. Peripheral blood examination showed hemoglobin level of 101 g/l, a platelet count of 65 Â 10 9 /l and a white blood cell count of 311 Â 10 9 /l with 44% neutrophils (136 Â 10 9 /l), 3% eosinophils (3 Â 10 9 /l), 2% monocytes (6.2 Â 10 9 /l), 46% promyelocytes, myelocytes and metamyelocytes and 2% circulating blasts. Bone marrow aspiration stained with May Grü nwald Giemsa was hypercellular, with granular hyperplasia, dysgranulopoiesis and few eosinophils. The diagnosis of myeloproliferative/ myelodysplastic syndrome was retained at that time because of the proliferative features, with dysplasia and very few monocytes in the bone marrow. Molecular analysis did not found any V617F or exon 12 mutation in JAK2, nor BCR-ABL1 fusion transcripts.
Reverse heat giemsa and G-trypsin giemsa banding chromosome analysis performed on bone marrow cells showed the following karyotype: 46,XX,t(2;8)(q12;p11) [14] /46,XX [14] (Figure 1a) , according to the 2009 International System for Human Cytogenetic Nomenclature. 5 Fluorescence in situ hybridization analysis with whole chromosome 2 and 8 painting probes (Kreatech, Strasbourg, France) confirmed the t(2;8)(q12;p11) ( Figure 1b) . Therefore, BAC RP11-350N15 encompassing the 8p11 FGFR1 gene region was hybridized and revealed signals on normal chromosome 8 and derivative chromosomes 2 and 8, demonstrating the breakpoint on 8p11 in FGFR1 gene.
In order to refine the breakpoint in chromosome 2, a series of BACs was hybridized on 2q12: RP11-38C17, RP11-350B7, RP11-443K8, RP11-465O11, RP11-85M14, RP11-348G16, RP11-84C2, RP11-20G1, RP11-471N11, RP11-566O4, RP11-528G9, RP11-438K19, RP11-368A17, RP11-412A2 and RP11-314L11 (BAC PAC Resource Center, Children's Hospital Oakland Research Institute and Dr E Flori, Cytogenetics Laboratory, Strasbourg University Hospital). BACs RP11-85M14, RP11-348G16 and RP11-84C2 showed signals on normal chromosome 2 and derivative chromosomes 2 and 8. Therefore, dual-color co-hybridization of BACs RP11-350N15 and RP11-84C2 showed fused signals on derivative chromosomes 2 and 8 ( Figure 1c ), narrowing the breakpoint region. RANBP2 (alias NUP358) gene was the sole known gene in the 2p12.3 region delineated by these probes, and we hypothesized that RANBP2 was a likely candidate for an inframe fusion with FGFR1. Thus, total RNA was extracted from bone marrow cells and a reverse transcription-PCR was designed to amplify a putative RANBP2-FGFR1 transcript, using one forward primer located in exon 16 of RANBP2 from Ma et al. 6 and one reverse primer located in exon 9 of FGFR1 from Hidalgo-Curtis et al. 7 We obtained specific amplification of the putative RANBP2/ NUP358-FGFR1, which was not obtained in controls. Sequence analysis of the three PCR products revealed three fusions of RANBP2 exon 20 with FGFR1 exon 9 (Figures 2a and b) . Only one of them was in-frame that incorporated 27 bp of intron 8 of FGFR1, the other presented abnormal splicing, and was not productive. The RANBP2-FGFR1 transcript sequence is predicted to encode a chimeric protein containing the N-terminal portion of the RANBP2 protein, including the protein interaction leucine zipper portion, and the two tyrosine kinase domains of FGFR1 ( Figure 2C ). The reciprocal transcript was also expressed, detected using FGFR1 forward primer from Soler et al. 8 and RANBP2 reverse primer from Ma et al. 6 (data not shown). Hydroxyurea and 6-mercaptopurin therapy was rapidly initiated. white blood cell count gradually decreased to a nadir of 2.9 Â 10 9 /l within 1 month. No related human leukocyte antigen-matched donor was identified. Allogenic hematopoietic stem cell transplant from an unrelated donor was not considered because of poor general condition. Disease progressed rapidly despite changes in therapy to subcutaneous cytarabine. Patient died 6 months after the diagnosis.
RANBP2/NUP358 is a component of the nuclear pore complex (NPC), localized at its cytoplasmic side. 9 It is the major component of cytoplasmic filaments of the pore and is involved in the final steps of nuclear export. RANBP2/NUP358 protein interacts with NUP88 in a NPC subcomplex and the latter also interacts with other proteins of the NPC, such as NUP214 and NUP98, NUP214 mediating the attachment of NUP358 to the NPC. 10 If NUP214 and NUP98 have recurrently been involved in hematopoietic tumors, RANBP2/NUP358 has mainly been implicated in a small subset of anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors, where a NUP358-ALK fusion was identified, resulting from a t(2;2)(p23;q13). 1, 11, 12 In these cases, the complementary DNA contained the first 18 exons of RANBP2/ NUP358, encoding the leucine zipper domain that has been proposed to be the site of attachment to the NPC core, and the cytoplasmic domain of the receptor tyrosine kinase ALK. 6 Recently, the same abnormality was detected in two juvenile myelomonocytic leukemias and one M4 acute myeloid leukemia, 13 associated to GM-CSF (granulocyte-macrophage colony-stimulating factor) hypersensitivity. The RANBP2/NUP358-FGFR1 fusion transcript identified in the case herein reported contained the first 20 exons of RANBP2/NUP358, coding for the same protein domains as in RANBP2/NUP358-ALK, and the two tyrosine kinase domains of FGFR1, and was also associated with a monocytosis.
In all fusion proteins involving FGFR1, the constitutive activation of the FGFR1 kinase is mediated by the N-terminus homodimerization motifs of the FGFR1 partners that promote leukemogenesis. These motifs in EMS are mainly coiled-coiled domains, and various motifs that are also implicated in protein-protein interaction (Supplementary table) . In the fusion transcript described in this study, the portion of RANBP2 includes a leucine zipper motif embedded in a leucine rich region, suggesting similar oncogenic mechanisms.
In addition to FGFR1 activation, FGFR1 partners are thought to have a specific role in the phenotypic expression of the disease. For instance, patients with t(8;22)(p11;q11) often present with a chronic myeloid leukemia (CML)-like clinical syndrome, and patients with t(8;13)(p11;q12), t(8;9)(p11;q33) and t(6;8)(q27;p11) are correlated with lymphadenopathy, peripheral blood monocytosis and polycythemia. 4 The CEP110-FGFR1 fusion protein that retains the leucine zipper motifs of CEP110 and the catalytic domain of FGFR1 is associated with monocytosis and shares structural similarities with the putative one of RANBP2/NUP358, which presented a monocytosis. In mice, the leucine-rich domain of RanBP2 also exhibits strong chaperone activity toward Cox11 proteins, supporting a chaperone role of RanBP2 in the cytosol. 14 The role of this protein interaction in the oncogenesis is not known, and COX11, to our knowledge, has not been reported to be associated with hematological malignancies or solid tumors.
Otherwise, in T lymphoblastic leukemia (T-ALL), the NUP214-ABL1 transcripts retain the N-terminal region of NUP214 including the predicted coiled-coiled domains (that may serve as oligomerization motifs) and the tyrosine kinase domain of ABL1.
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NUP98 fusion transcripts often have a different feature, including phenyl-alanine (FG) motifs that serve as interaction sites for karyopherins and chromatin interacting homeobox domains of the partner gene. In this study, we describe a novel fusion in hematological malignancies, expanding number of FGFR1 partner genes and confirming the relevance of RANBP2/NUP358 in myeloid neoplasm. The clinical presentation as a myeloproliferative/myelodysplastic disorder was not different from other EMS. More cases with chromosome 2 abnormalities should be explored in order to evaluate the incidence of RANBP2/NUP358 rearrangements in hematological neoplasms.
